Determinants of reduced cognitive performance in HIV-1-infected middle-aged men on combination antiretroviral therapy
OBJECTIVE:The spectrum of risk factors for HIV-associated cognitive impairment is likely very broad and includes not only HIV/antiretroviral therapy-specific factors but also other comorbid conditions. The purpose of this current study was to explore possible determinants for decreased cognitive per...
Gespeichert in:
| Veröffentlicht in: | AIDS (London) 2016-04, Vol.30 (7), p.1027-1038 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1038 |
|---|---|
| container_issue | 7 |
| container_start_page | 1027 |
| container_title | AIDS (London) |
| container_volume | 30 |
| creator | Schouten, Judith Su, Tanja Wit, Ferdinand W Kootstra, Neeltje A Caan, Matthan W.A Geurtsen, Gert J Schmand, Ben A Stolte, Ineke G Prins, Maria Majoie, Charles B Portegies, Peter Reiss, Peter |
| description | OBJECTIVE:The spectrum of risk factors for HIV-associated cognitive impairment is likely very broad and includes not only HIV/antiretroviral therapy-specific factors but also other comorbid conditions. The purpose of this current study was to explore possible determinants for decreased cognitive performance.
DESIGN AND METHODS:Neuropsychological assessment was performed on 103 HIV-1-infected men with suppressed viraemia on combination antiretroviral therapy for at least 12 months and 74 HIV-uninfected highly similar male controls, all aged at least 45 years. Cognitive impairment and cognitive performance were determined by multivariate normative comparison (MNC). Determinants of decreased cognitive performance and cognitive impairment were investigated by linear and logistic regression analysis, respectively.
RESULTS:Cognitive impairment as diagnosed by MNC was found in 17% of HIV-1-infected men. Determinants for decreased cognitive performance by MNC as a continuous variable included cannabis use, history of prior cardiovascular disease, impaired renal function, diabetes mellitus type 2, having an above normal waist-to-hip ratio, presence of depressive symptoms, and lower nadir CD4 cell count. Determinants for cognitive impairment, as dichotomized by MNC, included cannabis use, prior cardiovascular disease, impaired renal function, and diabetes mellitus type 2.
CONCLUSION:Decreased cognitive performance probably results from a multifactorial process, including not only HIV-associated factors, such as having experienced more severe immune deficiency, but also cardiovascular/metabolic factors, cannabis use, and depressive symptoms. |
| doi_str_mv | 10.1097/QAD.0000000000001017 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1808675997</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1777985132</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4357-6316c49f3340193a0dd0eba083c0bb091ba07266c80eefeebb7d82a18d6d32323</originalsourceid><addsrcrecordid>eNqFkUtLxDAUhYMoOj7-gUiXbqpJ0zbJUnyNIIigbkua3DrRNhmTdMR_b8ZRERd6s7hn8Z1zIQehfYKPCBbs-Pbk7Aj_GIIJW0MTUjKaVxUj62iCi1rkgjK8hbZDeEpQhTnfRFtFzaqiYGyCxjOI4AdjpY0hc13mQY8KdKbcozXRLCCbg--cH6RVkBmbTa8ecpIb24GKiRuM1j3k8nGpwWbOJuvQpsBokk6xxkP0bmG87LM4Ay_nb7too5N9gL3PvYPuL87vTqf59c3l1enJda5KWrG8pqRWpegoLTERVGKtMbQSc6pw22JBkmZFXSuOATqAtmWaF5JwXWtapLeDDle5c-9eRgixGUxQ0PfSghtDQzjm6SuEYP-jjDHBK_KRWq5Q5V0IHrpm7s0g_VtDcLPspkndNL-7SbaDzwtjO4D-Nn2VkQC-Al5dn0oJz_34Cr6Zgezj7O_sdxWcm6E</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1777985132</pqid></control><display><type>article</type><title>Determinants of reduced cognitive performance in HIV-1-infected middle-aged men on combination antiretroviral therapy</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Journals@Ovid Complete</source><creator>Schouten, Judith ; Su, Tanja ; Wit, Ferdinand W ; Kootstra, Neeltje A ; Caan, Matthan W.A ; Geurtsen, Gert J ; Schmand, Ben A ; Stolte, Ineke G ; Prins, Maria ; Majoie, Charles B ; Portegies, Peter ; Reiss, Peter</creator><creatorcontrib>Schouten, Judith ; Su, Tanja ; Wit, Ferdinand W ; Kootstra, Neeltje A ; Caan, Matthan W.A ; Geurtsen, Gert J ; Schmand, Ben A ; Stolte, Ineke G ; Prins, Maria ; Majoie, Charles B ; Portegies, Peter ; Reiss, Peter ; AGEhIV Study Group</creatorcontrib><description>OBJECTIVE:The spectrum of risk factors for HIV-associated cognitive impairment is likely very broad and includes not only HIV/antiretroviral therapy-specific factors but also other comorbid conditions. The purpose of this current study was to explore possible determinants for decreased cognitive performance.
DESIGN AND METHODS:Neuropsychological assessment was performed on 103 HIV-1-infected men with suppressed viraemia on combination antiretroviral therapy for at least 12 months and 74 HIV-uninfected highly similar male controls, all aged at least 45 years. Cognitive impairment and cognitive performance were determined by multivariate normative comparison (MNC). Determinants of decreased cognitive performance and cognitive impairment were investigated by linear and logistic regression analysis, respectively.
RESULTS:Cognitive impairment as diagnosed by MNC was found in 17% of HIV-1-infected men. Determinants for decreased cognitive performance by MNC as a continuous variable included cannabis use, history of prior cardiovascular disease, impaired renal function, diabetes mellitus type 2, having an above normal waist-to-hip ratio, presence of depressive symptoms, and lower nadir CD4 cell count. Determinants for cognitive impairment, as dichotomized by MNC, included cannabis use, prior cardiovascular disease, impaired renal function, and diabetes mellitus type 2.
CONCLUSION:Decreased cognitive performance probably results from a multifactorial process, including not only HIV-associated factors, such as having experienced more severe immune deficiency, but also cardiovascular/metabolic factors, cannabis use, and depressive symptoms.</description><identifier>ISSN: 0269-9370</identifier><identifier>EISSN: 1473-5571</identifier><identifier>DOI: 10.1097/QAD.0000000000001017</identifier><identifier>PMID: 26752277</identifier><language>eng</language><publisher>England: Copyright Wolters Kluwer Health, Inc</publisher><subject>AIDS/HIV ; Anti-Retroviral Agents - therapeutic use ; Antiretroviral Therapy, Highly Active ; Cardiovascular Diseases ; Cognitive Dysfunction - epidemiology ; Cognitive Dysfunction - etiology ; Depression ; HIV Infections - complications ; HIV Infections - drug therapy ; Humans ; Lentivirus ; Male ; Marijuana Abuse ; Middle Aged ; Prospective Studies ; Retroviridae ; Risk Factors</subject><ispartof>AIDS (London), 2016-04, Vol.30 (7), p.1027-1038</ispartof><rights>Copyright © 2016 Wolters Kluwer Health, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4357-6316c49f3340193a0dd0eba083c0bb091ba07266c80eefeebb7d82a18d6d32323</citedby><cites>FETCH-LOGICAL-c4357-6316c49f3340193a0dd0eba083c0bb091ba07266c80eefeebb7d82a18d6d32323</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26752277$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schouten, Judith</creatorcontrib><creatorcontrib>Su, Tanja</creatorcontrib><creatorcontrib>Wit, Ferdinand W</creatorcontrib><creatorcontrib>Kootstra, Neeltje A</creatorcontrib><creatorcontrib>Caan, Matthan W.A</creatorcontrib><creatorcontrib>Geurtsen, Gert J</creatorcontrib><creatorcontrib>Schmand, Ben A</creatorcontrib><creatorcontrib>Stolte, Ineke G</creatorcontrib><creatorcontrib>Prins, Maria</creatorcontrib><creatorcontrib>Majoie, Charles B</creatorcontrib><creatorcontrib>Portegies, Peter</creatorcontrib><creatorcontrib>Reiss, Peter</creatorcontrib><creatorcontrib>AGEhIV Study Group</creatorcontrib><title>Determinants of reduced cognitive performance in HIV-1-infected middle-aged men on combination antiretroviral therapy</title><title>AIDS (London)</title><addtitle>AIDS</addtitle><description>OBJECTIVE:The spectrum of risk factors for HIV-associated cognitive impairment is likely very broad and includes not only HIV/antiretroviral therapy-specific factors but also other comorbid conditions. The purpose of this current study was to explore possible determinants for decreased cognitive performance.
DESIGN AND METHODS:Neuropsychological assessment was performed on 103 HIV-1-infected men with suppressed viraemia on combination antiretroviral therapy for at least 12 months and 74 HIV-uninfected highly similar male controls, all aged at least 45 years. Cognitive impairment and cognitive performance were determined by multivariate normative comparison (MNC). Determinants of decreased cognitive performance and cognitive impairment were investigated by linear and logistic regression analysis, respectively.
RESULTS:Cognitive impairment as diagnosed by MNC was found in 17% of HIV-1-infected men. Determinants for decreased cognitive performance by MNC as a continuous variable included cannabis use, history of prior cardiovascular disease, impaired renal function, diabetes mellitus type 2, having an above normal waist-to-hip ratio, presence of depressive symptoms, and lower nadir CD4 cell count. Determinants for cognitive impairment, as dichotomized by MNC, included cannabis use, prior cardiovascular disease, impaired renal function, and diabetes mellitus type 2.
CONCLUSION:Decreased cognitive performance probably results from a multifactorial process, including not only HIV-associated factors, such as having experienced more severe immune deficiency, but also cardiovascular/metabolic factors, cannabis use, and depressive symptoms.</description><subject>AIDS/HIV</subject><subject>Anti-Retroviral Agents - therapeutic use</subject><subject>Antiretroviral Therapy, Highly Active</subject><subject>Cardiovascular Diseases</subject><subject>Cognitive Dysfunction - epidemiology</subject><subject>Cognitive Dysfunction - etiology</subject><subject>Depression</subject><subject>HIV Infections - complications</subject><subject>HIV Infections - drug therapy</subject><subject>Humans</subject><subject>Lentivirus</subject><subject>Male</subject><subject>Marijuana Abuse</subject><subject>Middle Aged</subject><subject>Prospective Studies</subject><subject>Retroviridae</subject><subject>Risk Factors</subject><issn>0269-9370</issn><issn>1473-5571</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUtLxDAUhYMoOj7-gUiXbqpJ0zbJUnyNIIigbkua3DrRNhmTdMR_b8ZRERd6s7hn8Z1zIQehfYKPCBbs-Pbk7Aj_GIIJW0MTUjKaVxUj62iCi1rkgjK8hbZDeEpQhTnfRFtFzaqiYGyCxjOI4AdjpY0hc13mQY8KdKbcozXRLCCbg--cH6RVkBmbTa8ecpIb24GKiRuM1j3k8nGpwWbOJuvQpsBokk6xxkP0bmG87LM4Ay_nb7too5N9gL3PvYPuL87vTqf59c3l1enJda5KWrG8pqRWpegoLTERVGKtMbQSc6pw22JBkmZFXSuOATqAtmWaF5JwXWtapLeDDle5c-9eRgixGUxQ0PfSghtDQzjm6SuEYP-jjDHBK_KRWq5Q5V0IHrpm7s0g_VtDcLPspkndNL-7SbaDzwtjO4D-Nn2VkQC-Al5dn0oJz_34Cr6Zgezj7O_sdxWcm6E</recordid><startdate>20160424</startdate><enddate>20160424</enddate><creator>Schouten, Judith</creator><creator>Su, Tanja</creator><creator>Wit, Ferdinand W</creator><creator>Kootstra, Neeltje A</creator><creator>Caan, Matthan W.A</creator><creator>Geurtsen, Gert J</creator><creator>Schmand, Ben A</creator><creator>Stolte, Ineke G</creator><creator>Prins, Maria</creator><creator>Majoie, Charles B</creator><creator>Portegies, Peter</creator><creator>Reiss, Peter</creator><general>Copyright Wolters Kluwer Health, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7T2</scope><scope>7T5</scope><scope>7U2</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope></search><sort><creationdate>20160424</creationdate><title>Determinants of reduced cognitive performance in HIV-1-infected middle-aged men on combination antiretroviral therapy</title><author>Schouten, Judith ; Su, Tanja ; Wit, Ferdinand W ; Kootstra, Neeltje A ; Caan, Matthan W.A ; Geurtsen, Gert J ; Schmand, Ben A ; Stolte, Ineke G ; Prins, Maria ; Majoie, Charles B ; Portegies, Peter ; Reiss, Peter</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4357-6316c49f3340193a0dd0eba083c0bb091ba07266c80eefeebb7d82a18d6d32323</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>AIDS/HIV</topic><topic>Anti-Retroviral Agents - therapeutic use</topic><topic>Antiretroviral Therapy, Highly Active</topic><topic>Cardiovascular Diseases</topic><topic>Cognitive Dysfunction - epidemiology</topic><topic>Cognitive Dysfunction - etiology</topic><topic>Depression</topic><topic>HIV Infections - complications</topic><topic>HIV Infections - drug therapy</topic><topic>Humans</topic><topic>Lentivirus</topic><topic>Male</topic><topic>Marijuana Abuse</topic><topic>Middle Aged</topic><topic>Prospective Studies</topic><topic>Retroviridae</topic><topic>Risk Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schouten, Judith</creatorcontrib><creatorcontrib>Su, Tanja</creatorcontrib><creatorcontrib>Wit, Ferdinand W</creatorcontrib><creatorcontrib>Kootstra, Neeltje A</creatorcontrib><creatorcontrib>Caan, Matthan W.A</creatorcontrib><creatorcontrib>Geurtsen, Gert J</creatorcontrib><creatorcontrib>Schmand, Ben A</creatorcontrib><creatorcontrib>Stolte, Ineke G</creatorcontrib><creatorcontrib>Prins, Maria</creatorcontrib><creatorcontrib>Majoie, Charles B</creatorcontrib><creatorcontrib>Portegies, Peter</creatorcontrib><creatorcontrib>Reiss, Peter</creatorcontrib><creatorcontrib>AGEhIV Study Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Safety Science and Risk</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>AIDS (London)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schouten, Judith</au><au>Su, Tanja</au><au>Wit, Ferdinand W</au><au>Kootstra, Neeltje A</au><au>Caan, Matthan W.A</au><au>Geurtsen, Gert J</au><au>Schmand, Ben A</au><au>Stolte, Ineke G</au><au>Prins, Maria</au><au>Majoie, Charles B</au><au>Portegies, Peter</au><au>Reiss, Peter</au><aucorp>AGEhIV Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Determinants of reduced cognitive performance in HIV-1-infected middle-aged men on combination antiretroviral therapy</atitle><jtitle>AIDS (London)</jtitle><addtitle>AIDS</addtitle><date>2016-04-24</date><risdate>2016</risdate><volume>30</volume><issue>7</issue><spage>1027</spage><epage>1038</epage><pages>1027-1038</pages><issn>0269-9370</issn><eissn>1473-5571</eissn><abstract>OBJECTIVE:The spectrum of risk factors for HIV-associated cognitive impairment is likely very broad and includes not only HIV/antiretroviral therapy-specific factors but also other comorbid conditions. The purpose of this current study was to explore possible determinants for decreased cognitive performance.
DESIGN AND METHODS:Neuropsychological assessment was performed on 103 HIV-1-infected men with suppressed viraemia on combination antiretroviral therapy for at least 12 months and 74 HIV-uninfected highly similar male controls, all aged at least 45 years. Cognitive impairment and cognitive performance were determined by multivariate normative comparison (MNC). Determinants of decreased cognitive performance and cognitive impairment were investigated by linear and logistic regression analysis, respectively.
RESULTS:Cognitive impairment as diagnosed by MNC was found in 17% of HIV-1-infected men. Determinants for decreased cognitive performance by MNC as a continuous variable included cannabis use, history of prior cardiovascular disease, impaired renal function, diabetes mellitus type 2, having an above normal waist-to-hip ratio, presence of depressive symptoms, and lower nadir CD4 cell count. Determinants for cognitive impairment, as dichotomized by MNC, included cannabis use, prior cardiovascular disease, impaired renal function, and diabetes mellitus type 2.
CONCLUSION:Decreased cognitive performance probably results from a multifactorial process, including not only HIV-associated factors, such as having experienced more severe immune deficiency, but also cardiovascular/metabolic factors, cannabis use, and depressive symptoms.</abstract><cop>England</cop><pub>Copyright Wolters Kluwer Health, Inc</pub><pmid>26752277</pmid><doi>10.1097/QAD.0000000000001017</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-9370 |
| ispartof | AIDS (London), 2016-04, Vol.30 (7), p.1027-1038 |
| issn | 0269-9370 1473-5571 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1808675997 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Journals@Ovid Complete |
| subjects | AIDS/HIV Anti-Retroviral Agents - therapeutic use Antiretroviral Therapy, Highly Active Cardiovascular Diseases Cognitive Dysfunction - epidemiology Cognitive Dysfunction - etiology Depression HIV Infections - complications HIV Infections - drug therapy Humans Lentivirus Male Marijuana Abuse Middle Aged Prospective Studies Retroviridae Risk Factors |
| title | Determinants of reduced cognitive performance in HIV-1-infected middle-aged men on combination antiretroviral therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T00%3A55%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Determinants%20of%20reduced%20cognitive%20performance%20in%20HIV-1-infected%20middle-aged%20men%20on%20combination%20antiretroviral%20therapy&rft.jtitle=AIDS%20(London)&rft.au=Schouten,%20Judith&rft.aucorp=AGEhIV%20Study%20Group&rft.date=2016-04-24&rft.volume=30&rft.issue=7&rft.spage=1027&rft.epage=1038&rft.pages=1027-1038&rft.issn=0269-9370&rft.eissn=1473-5571&rft_id=info:doi/10.1097/QAD.0000000000001017&rft_dat=%3Cproquest_cross%3E1777985132%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1777985132&rft_id=info:pmid/26752277&rfr_iscdi=true |